Real-World Data Linkage Research Platform

NCT07635355 · tracked via the Priya Life Science China tracker

Sponsor

Beijing Friendship Hospital

Phase

Observational

Started

2026-05-30

Last updated

2026-06-09

Condition(s) studied

Chronic DiseasesSub-optimal Health

Investigational drug(s) / intervention(s)

This is an observational study. No intervention will be applied.

This is an observational study. No intervention will be applied.: This is an observational study. No intervention will be applied.

Study summary

This study aims to address the lack of intelligent governance tools in clinical data management to promote efficient governance and secure sharing of real-world health data. To achieve this, a self-adaptive, automated governance intelligent agent will be developed based on a High-Order Programming (HOP) architecture, integrating Large Language Models (LLMs) and deep learning techniques. The agent will continuously monitor and correct data quality issues in real time, improving data accuracy and usability.

In parallel, the project will establish a trusted data-sharing framework by integrating AI Confidential Computing (AICC) with Trusted Data Matrix (TDM) technologies. This framework will enable secure, real-time cross-institutional data exchange and collaborative computation while protecting sensitive information.

Overall, the study aims to transform fragmented clinical data into high-quality, standardized, and securely accessible resources, thereby facilitating the circulation of data value and advancing collaborative medical research.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: * Participants will be eligible for inclusion if they meet all of the following criteria: 1. Availability of any health-related data generated from routine clinical care, health examinations, or disease surveillance systems, regardless of disease type or health status. 2. Presence of at least one type of usable data, including but not limited to diagnostic information (structured or unstructured), laboratory results, imaging data, or basic demographic information. 3. Records contain sufficient information (appropriately anonymized) to allow data organization and, where feasible, linkage at the individual level across time points or data sources. Exclusion Criteria: * Participants or records meeting any of the following criteria will be excluded: 1. Records lacking minimal essential information required to distinguish individual records or support basic analysis (e.g., completely missing identifiers or time information). 2. Records confirmed to be invalid, including system-generated test data, corrupted entries, or records that do not represent real clinical or health-related events. 3. Exact duplicate records that cannot be resolved through standard data processing (only one record will be retained when duplicates are identifiable).

Primary outcome measure(s)

Accuracy Rate of Automated Data Governance — 2026.5.30 to 2028.12.31
Using a manually curated gold-standard dataset, the effectiveness of the intelligent agent in improving data accuracy will be evaluated by measuring the proportion of data values that correctly match the gold-standard reference after automated data governance. The accuracy rate will be calculated as the percentage of correctly recorded or corrected data elements among all evaluated data elements. Values range from 0% to 100%, with higher values indicating better data accuracy.
Completeness Rate of Automated Data Governance — 2026.5.30 to 2028.12.31
Using a manually curated gold-standard dataset, the effectiveness of the intelligent agent in improving data completeness will be evaluated by measuring the proportion of required data fields that are complete after automated data governance. The completeness rate will be calculated as the percentage of non-missing required data elements among all required data elements. Values range from 0% to 100%, with higher values indicating better data completeness.

Trial sites (1)

Facility	City	Region	Status
Beijing Friendship Hospital, Capital Medical University.No. 95, Yongan Road, Xicheng District, Beijing, 100050, China	Beijing	Beijing Municipality

More Beijing Friendship Hospital trials in China

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer Active, not recruiting

Golidocitinib Combined With Selinexor for CAEBVD Recruiting

Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity Starting soon

The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis Starting soon

Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer（IDEAL Stage 2b） Recruiting

Other trials for the same condition

Precision Nutrition and Food Safety for Dietary Prevention of Chronic Disease Study Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07635355 on ClinicalTrials.gov ↗ ← All trials in China